Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease

Wilkinson, D., Murray, J., the Galantamine Research Group · 2001 · International Journal of Geriatric Psychiatry

Abstract

Objectives: To investigate whether Galantamine significantly improves the core symptoms of Alzheimer's disease (AD). Background: Galantamine is a reversible, competitive, selective inhibitor of acetylcholinesterase (AChE) that also allosterically modulates nicotinic acetylcholine receptors. This dual mechanism of action provided the rationale for a phase II trial of galantamine in AD. Method: A multicentre, randomized, parallel, double‐blind, placebo‐controlled trial was carried out to evaluate the efficacy and tolerability of galantamine 18, 24 and 36 mg/day administered for 3 months in 285 patients with mild‐to‐moderate probable AD. The primary outcome measure was the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog); secondary outcome measures were the Clinical Global Impression of Change (CGIC) and the Progressive Deterioration Scale (PDS). Results: Patients treated with galantamine 24 mg/day had a significantly better outcome than placebo on ADAS‐cog; the treatment difference was 3 points on the intention‐to‐treat (ITT) analysis ( p = 0.01) and 4.2 points on per protocol analysis ( p = 0.001). Per protocol analysis showed that galantamine had a significantly better outcome than placebo on PDS ( 24‐mg/day dose, p < 0.05) and CGIC (36‐mg/day dose, p < 0.05). Galantamine was well tolerated at the lower doses of 18 and 24 mg/day where it produced mild, transient effects typical of cholinomimetic agents. Conclusion: This study shows that, relative to placebo, galantamine significantly improves the core symptoms of Alzheimer's disease. Copyright © 2001 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gps.409

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 212

Metadata

Authors
Wilkinson, D., Murray, J., & the Galantamine Research Group
Venue
International Journal of Geriatric Psychiatry
Publisher
Wiley
Published
2001-09
Volume
16
Issue
9
Pages
852-857
ISSN
  • 0885-6230 (ISSN-L)
  • 1099-1166
OpenAlex
W2151603390
Cited by
212
References
4
FWCI
10.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease. https://app.cochat.ai/papers/10.1002/gps.409
The paper
Wilkinson, D., Murray, J., & the Galantamine Research Group. (2001). Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.409

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.